Asia Pacific obesity drug pipeline led by China as Korea gains ground

China holds 21 of the 30 candidates in the Asia Pacific obesity drug pipeline, according to a KoreaBIO report released on 2 November. South Korea follows with six, ahead of Japan with two and India with one. The tally, built on counts by Biopharma APAC, lands in a year when drug makers in the region have started to win approvals at home instead of only licensing compounds to Western partners. For Korea, the question is whether six candidates and one new launch are enough to keep China in sight.

How KoreaBIO counted 30 candidates

The KoreaBIO report, as reported by Chosun Biz, says companies based in the region have discovered 30 obesity drug candidates so far. The count covers medicines already approved as new drugs and candidates in clinical trials in the United States or China. That means it measures where a molecule was first found, not who sells it today or where it will reach patients first. A compound discovered in Japan and licensed to an American group still counts for Japan. The association did not publish the full list of molecules in the material summarised by the newspaper, so readers abroad cannot yet check each entry or see how candidates in early lab work were treated. The table below sets out the country totals and the main milestone the report names for each market.

The gap between the first two countries is wide. China accounts for seven in ten of the Asia Pacific obesity drug pipeline in this count, while Korea holds one in five. Japan's two candidates and India's single entry show how concentrated discovery work has become in two markets. The stage breakdown reported for China also does not add up to its full total, which suggests some candidates sit outside the phases the summary lists. KoreaBIO framed the picture as a race in which China is speeding up and Korea is chasing. That is an industry group's reading of a pipeline count, not a measure of sales, prices or patient access, and pipeline numbers tend to shrink as candidates fail or stall in later trials.

China moves first with an ecnoglutide approval

The clearest Chinese milestone in the report is Sciwind's ecnoglutide. The National Medical Products Administration approved it for obesity in March, according to the association. Ecnoglutide copies the action of glucagon like peptide 1, or GLP 1, a gut hormone released after meals. The report says the drug slows how fast food leaves the stomach and makes people feel full sooner. That places it in the same broad family as semaglutide in Wegovy and tirzepatide in Mounjaro, the two brands the report names as the drugs Asian makers are now chasing. A home grown ecnoglutide approval matters in China because a local maker controls the molecule, the plant and the price talks. The report did not give a launch date, a price or a reimbursement decision for the drug.

In China, three more obesity candidates are awaiting a decision from regulators, ten have started or finished Phase 3 trials and four sit in Phase 1 or 2.

In China, three more obesity candidates are awaiting a decision from regulators, ten have started or finished Phase 3 trials and four sit in Phase 1 or 2. That is a deep queue for one market. It means Chinese doctors and payers may soon weigh several local GLP 1 class options against imported brands. It also sits beside a second wave of competition, since more than ten local firms have been preparing Chinese semaglutide copies as the main patent runs out. The report does not say which of the late stage candidates are new molecules and which are close followers of existing drugs, nor does it name the companies behind most of them. Those details will decide how crowded each slice of the Chinese market becomes.

Hanmi efpeglenatide leads the Korean push

In Korea, the Ministry of Food and Drug Safety approved Hanmi Pharmaceutical's obesity drug in October, and the company has launched it. This site has identified the medicine as Hanmi efpeglenatide, sold as Epe, and our earlier report found the pen reached selected Korean clinics on 29 October with limited stock. The KoreaBIO report describes it as a GLP 1 class drug with relatively fewer side effects such as vomiting, a claim the published summary does not back with trial figures. Hanmi is also working on a candidate that acts on three targets at once: the GLP 1 receptor, the receptor for gastric inhibitory polypeptide, or GIP, and the glucagon receptor. A further Hanmi project aims to cut weight while keeping muscle.

Other Korean biotech groups are further back. Dong-A ST is developing a candidate through its affiliate Metavia that is meant to curb appetite and raise basal metabolic rate. It is in Phase 1, and the association said key results could be disclosed within the year. Yuhan's affiliate ProGen and LG Chem also have obesity candidates in development, though the report gives no stage or target for them. The summary does not mention Daewon Pharmaceutical, which is testing an oral semaglutide candidate of its own, because the tally tracks new candidates rather than copies of existing ingredients. Korea's six entries therefore show a mix of one approved product, several early programmes and a few undisclosed ones, which is a thinner base than China's long late stage list.

Oral obesity drug licensing and the next test

Japan's main contribution shows the older model. Chugai Pharmaceutical discovered an oral obesity drug candidate and licensed the technology to Eli Lilly in 2018. According to the report, Lilly won approval from the US Food and Drug Administration in April this year and launched the pill under its own brand. KoreaBIO expects oral treatments to grow the market further because patients find a pill more convenient to take. That is the association's forecast, not a measured result. For years, the report says, firms behind the Asia Pacific obesity drug pipeline mostly found candidates and sold the rights to overseas drug makers. This year, it adds, some have begun to finish trials and bring an oral obesity drug or injection to market themselves, which brings them into direct contest with the global brands.

KoreaBIO also named the factors it thinks will decide the contest. "Going forward, not only the amount of weight loss but also price, supply capacity, and dosing interval will be key competitive factors," the association said, in the newspaper's English rendering. Supply is already a live issue in the region: an Indian maker paused its generic semaglutide pens this year after a production problem, and Hanmi's first Korean stock is limited. The next checkpoints are concrete. Dong-A ST and Metavia may publish early results before the end of 2026, the three Chinese candidates awaiting review need decisions from the NMPA, and Hanmi has to show it can keep pens on Korean shelves. The report fixed none of those dates.

Conclusion

The KoreaBIO count puts China well ahead in the Asia Pacific obesity drug pipeline, with 21 of 30 candidates, one approved drug and a long line in late stage trials. Korea has six candidates and one fresh launch, while Japan's best known candidate was licensed to Lilly years ago. The figures describe discovery and trial activity, not sales or patient access, and the association has not yet published its full list. Approvals in China and early data from Korea will show whether the gap holds.